Biological Activity:
GSK461364, a selective i.v. thiophene amide inhibitor of PLK1, induced selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. GSK461364 is an ATP-competitive inhibitor of Plk1 and forms a rapidly reversible complex with Plk1. It has a 400-fold greater potency for Plk1 than for Plk2 and Plk3.In vitro, this compound showed antiproliferative activity in £¾120 cancer cell lines tested. IC50 values were £¼50 nM in £¾83% of the cell lines tested. GSK461364 demonstrated tumor growth inhibition in animal models. In these xenograft models, GSK461364 showed antitumor activity ranging from complete tumor growth inhibition to growth delay. Interestingly, the compound caused dose-dependent mitotic arrest in Colo205 xenografts in vivo.
Related Compounds:
S1109 BI 2536 :Potent and selective polo-like kinase (PLK) 1 inhibitor,IC50 0.8 nM.
Technical Data:
M.Wt: 543.6
Formula: C27H28F3N5O2S
Solubility: Unknown
Purity: >99%
Storage: -20C 2 years
CAS No: 929095-18-1
References:
1. Schöffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist. 2009 Jun;14(6):559-70. Epub 2009 May 27.
2. Laquerre S, Sung C-M, Gilmartin A et al. A potent and selective Polo-like kinase 1 (Plk1) inhibitor (GSK461364) induces cell cycle arrest and growth inhibition of cancer cell. Presented at the 98th American Association for Cancer Research Annual Meeting, Los Angeles, CA, April 14¨C18, 2007.
3. Erskine S, Madden L, Hassler D et al. Biochemical characterization of GSK461364: A novel, potent, and selective inhibitor of Polo-like kinase-1 (Plk1). Presented at the 98th American Association for Cancer Research Annual Meeting, Los Angeles, CA, April 14¨C18 2007.
4. Sutton D, Diamond M, Faucette L et al. Efficacy of GSK461364, a selective Plk1 inhibitor, in human tumor xenograft models. Presented at the 98th American Association for Cancer Research Annual Meeting, Los Angeles, CA, April 14¨C18, 2007.
5. Blagden S, Olmos D, Sharma R et al. A phase I first-in-human study of the Polo-like kinase 1-selective inhibitor, GSK461364, in patients with advanced solid tumors. Presented at the 20th European Organization for Research and Treatment of Cancer¨CNational Cancer Institute¨CAmerican Association for Cancer Research Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland, October 21¨C24, 2008.
6. Palmieri D, Hua E, Qian Y et al. Preclinical studies investigating the efficacy of GSK461364A, an inhibitor of Polo-like kinase-1, for the prevention of breast cancer brain metastases. Presented at the American Association for Cancer Research 2009 Annual Meeting, Denver, CO, April 18 ¨C22, 2009
如果您想追踪小分子靶向ZL的进展,有意加入靶向ZL研究的行列,
欢迎致信binxinbio@163.com索取详细资料,
我们定期将肿瘤靶向ZL的进展发给您。
我们的合作也许能带给您不是一桶金,而是很多桶金!
温馨提示:不可用于临床ZL。